36.89 +0.39 (1.07%)
After hours: 4:21PM EST
|Bid||35.80 x 1000|
|Ask||36.75 x 1000|
|Day's range||36.25 - 37.47|
|52-week range||29.39 - 45.87|
|PE ratio (TTM)||29.51|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||43.06|
Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.
Mylan President Rajiv Malik, who has been paid $53.8 million over three years, has been targeted by 45 state attorneys general for allegedly fixing the prices of drugs.
A British billionaire is considering buying a stake in Teva, reports say, prodding shares of the Israeli drugmaker to pop.
Mylan missed third-quarter sales and earnings expectations, but issued better-than-expected sales guidance for 2017.
Sinking EpiPen sales and a weak U.S. generic market hurt the drugmaker in Q3, but its full-year outlook got a boost.
It's been a tough year for generic drug makers' shares, but it looks like Mylan (MYL) may be able to beat competitor Teva Pharmaceutical Industries (TEVA) at its own game: a generic drug. Mylan raised ...
Little has gone right for Mylan recently, so the company and its investors can be forgiven for embracing a new drug as its next engine for growth.
Broadcom, Qualcomm, Sprint, T-Mobile, CVS, Mylan and Michael Kors are among the stocks to watch.
We see see what appears to be a hostile bid by Broadcom (AVGO) to take over Qualcomm (QCOM) for $70 per share, or $130 billion, including $60 billion in cash and Qualcomm debt.
Shares of Mylan (MYL) are climbing today after the drug maker tightened its full-year guidance, raising the lower end of its 2017 revenue and per-share earnings forecasts to reflect the earlier-than-expected approval of its generic version of Teva Pharmaceutical Industries (TEVA) blockbuster multiple sclerosis treatment Copaxone. RBC Capital Markets analyst Randall Stanicky said “it could have been worse,” adding that much will now depend on whether Mylan’s pipeline can deliver products to offset generic pricing erosion. The weakness was not surprisingly sourced from North America, likely a combination of EpiPen impact and US generic headwinds and saw roughly $0.06 of EPS support from lower spend in the quarter implying it could have been worse...Overall, results suggest more of the same in that sector headwinds are continuing consistent with most of our data points heading into 3Q and the question for MYL will be whether its higher barrier pipeline can help deliver through continued erosion headwinds.
Mylan Inc. (MYL) on Monday reported third-quarter net income of $88.3 million, after reporting a loss in the same period a year earlier. The Hatfield, Britain-based company said it had net income of 16 ...
Mylan N.V. shares fell 4% in premarket trade Monday, after the drug company missed estimates for third-quarter earnings. The company said it had net income of $88.3 million, or 16 cents a share, after ...
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.
Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.